Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus

Novartis100 enrolled

Overview

The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Secondary outcomes: safety

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Coronary Heart Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cardiac transplant recipients * Discharged alive from hospital * Must be receiving everolimus Exclusion Criteria: * Patients not treated with everolimus beginning within 2 weeks after receiving a heart transplant Other inclusion/exclusion criteria may apply.

Locations (6)

Novarits

Graz, Austria

Novartis Investigative Site

Innsbruck, Austria

Novartis

Wein, Austria

Novartis

Bad Oeynhausen, Germany

Novartis Investigative Site

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.